Journal
NATURE
Volume 550, Issue 7675, Pages 280-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/nature24049
Keywords
-
Categories
Funding
- Paul and Daisy Soros Fellowship and a National Defense Science and Engineering Fellowship
- D.G.E. Computational Science Graduate Fellowship
- Howard Hughes Medical Institute
- National Institutes of Health through the National Institute of Mental Health [5DP1-MH100706, 1R01-MH110049]
- New York Stem Cell Foundation
- Simons Foundation
- Paul G. Allen Family Foundation
- Vallee Foundation
Ask authors/readers for more resources
RNA has important and diverse roles in biology, but molecular tools to manipulate and measure it are limited. For example, RNA interference(1-3) can efficiently knockdown RNAs, but it is prone to off-target effects(4), and visualizing RNAs typically relies on the introduction of exogenous tags(5). Here we demonstrate that the class 2 type VI6,7 RNA-guided RNA-targeting CRISPR-Cas effector Ca.s13a(8) (previously known as C2c2) can be engineered for mammalian cell RNA knockdown and binding. After initial screening of 15 orthologues, we identified Cas13a from Leptotrichia wadei (LwaCasl3a) as the most effective in an interference assay in Escherichia coli. LwaCasl3a can be heterologously expressed in mammalian and plant cells for targeted knockdown of either reporter or endogenous transcripts with comparable levels of knockdown as RNA interference and improved specificity. Catalytically inactive LwaCasl3a maintains targeted RNA binding activity, which we leveraged for programmable tracking of transcripts in live cells. Our results establish CRISPR-Cas13a as a flexible platform for studying RNA in mammalian cells and therapeutic development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available